Title
Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Phase
Phase 3Lead Sponsor
HOVON - Dutch Haemato-Oncology AssociationStudy Type
InterventionalStatus
Active, not recruitingIndication/Condition
Multiple MyelomaIntervention/Treatment
urea lenalidomide prednisone bortezomib melphalan ...Study Participants
1503Study phase: phase III
Study objective:
Comparison of Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed autologous stem cell transplantation (ASCT)
Comparison of Bortezomib, Lenalidomide, Dexamethasone(VRD) as consolidation versus no consolidation
Comparison of single versus tandem high dose Melphalan with ASCT
Patient population: Patients with symptomatic multiple myeloma,previously untreated, ISS stages 1-3, age 18-65 years inclusive
Study design: Prospective, multicenter, intergroup, randomized
Duration of treatment: Expected duration of induction, stem cell collection and intensification is 6 - 9 months. Consolidation with VRD will last 2 months Maintenance therapy with Lenalidomide will be given until relapse. All patients will be followed until 10 years after registration.
Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11,22,25,29,32 Melphalan _ 9 mg/m² _ p.o. _ days 1-4 Prednisone _ 60 mg/m² _ p.o. _ days 1-4
- Melphalan _ 100 mg/m² _ i.v. rapid infusion _ -3, -2* *Patients with renal insufficiency 100 mg/m2 only at day -3 If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR.
Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11 Lenalidomide _ 25 mg _ p.o. _ days 1-21 Dexamethasone _ 20 mg _ p.o. _ days 1,2,4,5,8,9,11,12
All patients randomized to VMP treatment, will be treated with Bortezomib, Melphalan, Prednisone(VMP, 4 cycles) and will start intensification with VMP between 4 and 6 weeks after stem cell collection.
All patients randomized to intensification with High Dose Melphalan will start intensification with HDM (in hospitals with a policy of double intensification, patients will be randomized between VMP, 1 HDM and 2 HDM) between 4 and 6 weeks after stem cell collection.
No consolidation, patients will continue to Lenalidomide maintenance.
In patients randomized to consolidation treatment, 2 cycles of Bortezomib, Lenalidomide,Dexamethasone (VRD) will start at 8 weeks after the end of the last course of VMP or HDM.
Inclusion Criteria: Patients with a confirmed diagnosis of symptomatic multiple myeloma stage I to III according to the International Staging System ISS (see appendix A), i.e. at least one of the CRAB criteria should be present; Measurable disease as defined by the presence of M-protein in serum or urine (serum M-protein> 10 g/l or urine M-protein > 200 mg/24 hours), or abnormal free light chain ratio; Age 18-65 years inclusive; WHO performance status 0-3 (WHO=3 is allowed only when caused by MM and not by comorbid conditions); Negative pregnancy test at inclusion if applicable; Written informed consent. Inclusion for randomisation 1: WHO performance 0-2; Bilirubin and transaminases < 2.5 times the upper limit of normal values; A suitable stem cell graft containing at least 4 x 106 CD34+ cells/kg (or according to national guidelines). Inclusion for randomisation 2: Bilirubin and transaminases < 2.5 times the upper limit of normal values; ANC >= 0.5 x 109/l and platelets > 20 x 10^9/l; Patient is able to adhere to the requirements of the Lenalidomide Pregnancy Prevention Risk Management Plan. Exclusion Criteria: Known intolerance of Boron; Systemic AL amyloidosis; Primary Plasmacell Leukemia; Non-secretory MM; Previous chemotherapy or radiotherapy except local radiotherapy in case of local myeloma progression or corticosteroids maximum 5 days for symptom control; Severe cardiac dysfunction (NYHA classification II-IV); Significant hepatic dysfunction, unless related to myeloma; Patients with GFR <15 ml/min, Patients known to be HIV-positive; Patients with active, uncontrolled infections; Patients with neuropathy, CTC grade 2 or higher; Patients with a history of active malignancy during the past 5 years with the exception of basal carcinoma of the skin or stage 0 cervical carcinoma; Patients who are not willing or capable to use adequate contraception during the therapy (all men, all pre-menopausal women); Lactating women. Exclusion for randomisation 1: Severe pulmonary, neurologic, or psychiatric disease; CTCAE grade 3-4 polyneuropathy during Bortezomib treatment; Allogeneic Stem Cell Transplantation (Allo SCT) planned; Progressive disease.' Exclusion for randomisation 2: Progressive disease; Neuropathy, except CTCAE grade 1; CTCAE grade 3-4 polyneuropathy during Bortezomib treatment.
